Special Issue

Viruses and Endothelial Dysfunction

Message from the Guest Editor

The introduction of cART, has considerably decreased the viral burden and opportunistic infections and increased the life expectancy in HIV+-infected people. Conversely, HIV+ individuals develop a greater vulnerability to non-AIDS-related complications. In particular, HIV+ patients have a higher risk of developing endothelial dysfunction, which may occur in both the absence and presence of suppressive cART. HIV-1encoded proteins are expressed in HIV+ individuals, even in the absence of viral replication, and are able to induce strong changes in endothelial cell (EC) physiology and morphology, to induce direct EC damage and to develop an inflammatory microenvironment. As a consequence, viral proteins may represent some of the essential factors involved in the development of endothelial disorders in AIDS. Understanding the key role of some HIV-1 protein in sustaining EC aberrant functioning may help in identifying new therapeutic approaches for combating and preventing HIV-1-related vascular diseases. All researchers working in the field are cordially invited to contribute original research papers or propose reviews to feature in this Special Issue.

Guest Editor

Dr. Francesca Caccuri

Department of Molecular and Translational Medicine, Section of Microbiology, University of Brescia Medical School, Brescia, Italy

Deadline for manuscript submissions

closed (1 July 2023)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/40294

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAq, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).